BQ Journal Vol 54 - Q1 2024 - 30

AREXVY
(Respiratory Syncytial Virus Vaccine, Adjuvanted)
(Respiratory Syncytial Virus Vaccine, Adjuvanted)
Respiratory Syncytial Virus Vaccine, Adjuvanted
Respiratory Syncytial Virus Vaccine, Adjuvanted
0.5-mL SDV
0.5-mL SDV
Code: 90679†
Code: 90679†
(145-4809)............................................................... 10/box
CPT®
(145-4809)............................................................... 10/box
CPT®
Indication
* AREXVY is indicated for active immunization for
the prevention of lower respiratory tract disease
(LRTD) caused by respiratory syncytial virus in
individuals 60 years of age and older.
Source: www.arexvyhcp.com
Indication
* AREXVY is indicated for active immunization for
the prevention of lower respiratory tract disease
(LRTD) caused by respiratory syncytial virus in
individuals 60 years of age and older.
Source: www.arexvyhcp.com
ABRYSVO™
(Respiratory Syncytial Virus Vaccine)
(Respiratory Syncytial Virus Vaccine)
* ABRYSVO is a vaccine indicated for:
The prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in people 60 years
of age and older
(145-4487).......................................................................ea
Respiratory Syncytial Virus Vaccine, Prefilled Syringe
0.5 mL
(145-4488)................................................................. 5/box
CPT® Code: 90678†
CPT® Code: 90678†
0.5 mL
(145-4488)................................................................. 5/box
(145-4487).......................................................................ea
Respiratory Syncytial Virus Vaccine, Prefilled Syringe
* ABRYSVO is a vaccine indicated for:
The prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in people 60 years
of age and older
*Pregnant individuals at 32 through 36 weeks gestational age
for the prevention of LRTD and severe LRTD caused by RSV in
infants from birth through 6 months of age
Source: www.abrysvo.com
Source: www.abrysvo.com
*Pregnant individuals at 32 through 36 weeks gestational age
for the prevention of LRTD and severe LRTD caused by RSV in
infants from birth through 6 months of age
Diagnostics I Pharmaceuticals I DxRx Solutions I Continuing Education I News
A HENRY SCHEIN PUBLICATION
BIOTHERAPEUTICS
Diagnostic and Pharmaceutical News for You and Your Medical Practice
30

http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx%3Fproductid%3D1454809%26CatalogName%3DMEDICAL%26utm_source%3DMedical%26utm_medium%3DNxtbook%26utm_campaign%3Dbqjournal-q1-2024%26utm_term%3D1454809 http://www.arexvyhcp.com http://www.abrysvo.com http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx%3Fproductid%3D1454487%26CatalogName%3DMEDICAL%26utm_source%3DMedical%26utm_medium%3DNxtbook%26utm_campaign%3Dbqjournal-q1-2024%26utm_term%3D1454487 http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx%3Fproductid%3D1454488%26CatalogName%3DMEDICAL%26utm_source%3DMedical%26utm_medium%3DNxtbook%26utm_campaign%3Dbqjournal-q1-2024%26utm_term%3D1454488

BQ Journal Vol 54 - Q1 2024

Table of Contents for the Digital Edition of BQ Journal Vol 54 - Q1 2024